Traders Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 38,662 call options on the company. This represents an increase of approximately 44% compared to the typical volume of 26,826 call options.

Wall Street Analyst Weigh In

SLS has been the subject of a number of analyst reports. Maxim Group boosted their target price on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, SELLAS Life Sciences Group currently has an average rating of “Hold” and an average target price of $10.00.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Several large investors have recently bought and sold shares of SLS. Anson Funds Management LP boosted its stake in SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after acquiring an additional 5,757,938 shares in the last quarter. Marshall Wace LLP boosted its stake in SELLAS Life Sciences Group by 23,550.0% in the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock valued at $5,947,000 after acquiring an additional 2,704,007 shares in the last quarter. Geode Capital Management LLC boosted its stake in SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock valued at $4,819,000 after acquiring an additional 1,379,988 shares in the last quarter. Millennium Management LLC boosted its stake in SELLAS Life Sciences Group by 341.0% in the fourth quarter. Millennium Management LLC now owns 1,387,849 shares of the company’s stock valued at $5,232,000 after acquiring an additional 1,073,147 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of SELLAS Life Sciences Group by 60.8% during the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock worth $8,249,000 after buying an additional 827,257 shares during the period. Institutional investors and hedge funds own 17.38% of the company’s stock.

SELLAS Life Sciences Group Price Performance

NASDAQ SLS opened at $6.53 on Thursday. SELLAS Life Sciences Group has a 1 year low of $1.39 and a 1 year high of $6.72. The company has a market capitalization of $1.20 billion, a PE ratio of -28.39 and a beta of 2.24. The company has a fifty day moving average of $4.98 and a two-hundred day moving average of $3.67.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.